Multiple Myeloma

Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

David Samuel Dicapua Siegel, MD, discusses unmet needs and current challenges within multiple myeloma.

The EMA has accepted a marketing authorization application seeking approval of belantamab mafodotin regimens in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD, highlights how therapeutic improvements with quadruplet regimens will benefit all patients with newly diagnosed multiple myeloma.

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD, discusses the use of quadruplet regimens in patients with newly diagnosed multiple myeloma.

Noa Biran, MD, discusses the impact of the IMROZ trial in the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma.

Francisco Hernandez-Ilizaliturri, MD, discusses selection and sequencing considerations for bispecific antibodies and CAR T-cell therapies in DLBCL.

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Alfred L. Garfall, MD, MS discusses updated long-term data for teclistamab in patients with relapsed/refractory multiple myeloma.

Amrita Krishnan, MD, discusses the characteristics and factors associated with a higher risk of early relapse for patients with multiple myeloma.

Noa Biran, MD, discusses key data from clinical trials in multiple myeloma presented at the 2024 ASCO Annual Meeting.

DREAMM-8 (NCT04484623) is an ongoing, randomized, open-label, phase 3 study evaluating BPd vs PVd in patients with RRMM previously treated with ≥1 line of therapy including lenalidomide.

Noa Biran, MD, discusses avenues for future research and drug development in multiple myeloma.

Mohamad Mohty, MD, PhD, shares the rationale for investigating the real-world efficacy of elranatamab in relapsed/refractory multiple myeloma.

Cilta-cel improved overall survival vs standard regimens in relapsed/lenalidomide-refractory multiple myeloma after 1 prior line of therapy.

Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, discusses strategies to improve the benefits of CAR T-cell therapy in multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses subgroup results for belantamab mafodotin plus bortezomib/dexamethasone in relapsed/refractory myeloma

DREAMM-7 (NCT04246047) is a global, randomized, open-label, phase III head-to-head trial evaluating the efficacy and safety of BVd triplet vs SoC triplet, DVd, in patients (pts) with RRMM with ≥1 prior line of therapy.

Mohamad Mohty, MD, PhD, discusses the real-world efficacy of elranatamab in patients with relapsed/refractory multiple myeloma.

The FDA has modified the risk evaluation and mitigation strategies for CAR T-cell therapies approved for hematologic malignancies.

James Ignatz-Hoover, MD, PhD, discusses the future of CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma.

Bertrand Arnulf, MD, PhD, discusses patient factors and pharmacodynamic biomarkers that impact survival outcomes with ide-cel in multiple myeloma.

IMROZ (NCT03319667) is the first global Phase 3 study of an anti-CD38 mAb in combination with VRd in patients with transplant-ineligible NDMM.